Pharmaceuticals

  • Read more: REGISTER NOW! Will Value-based Care Save the Health Care System?

    REGISTER NOW! Will Value-based Care Save the Health Care System?

    Will Value-based Care Save the Health Care System? March 2, 2018 9:00 AM – 5:00 PM Wasserstein Hall, Milstein East ABC (2036) Harvard Law School, 1585 Massachusetts Ave., Cambridge, MA Value-based health care is one of the most pressing topics in health care finance and policy today. Value-based payment structures are widely touted as critical to…

  • Read more: REGISTER NOW! Will Value-based Care Save the Health Care System?

    REGISTER NOW! Will Value-based Care Save the Health Care System?

    Will Value-based Care Save the Health Care System? March 2, 2018 9:00 AM – 5:00 PM Wasserstein Hall, Milstein East ABC (2036) Harvard Law School, 1585 Massachusetts Ave., Cambridge, MA Value-based health care is one of the most pressing topics in health care finance and policy today. Value-based payment structures are widely touted as critical to…

  • Read more: Simulated Side Effects: FDA Uses Novel Computer Model to Guide Kratom Policy

    Simulated Side Effects: FDA Uses Novel Computer Model to Guide Kratom Policy

    By Mason Marks FDA Commissioner Scott Gottlieb issued a statement on Tuesday about the controversial plant Mitragyna speciosa, which is also known as kratom. According to Gottlieb, kratom poses deadly health risks. His conclusion is partly based on a computer model that was announced in his recent statement. The use of simulations to inform drug…

  • Read more: REGISTER NOW! Will Value-based Care Save the Health Care System?

    REGISTER NOW! Will Value-based Care Save the Health Care System?

    Will Value-based Care Save the Health Care System? March 2, 2018 9:00 AM – 5:00 PM Wasserstein Hall, Milstein East ABC (2036) Harvard Law School, 1585 Massachusetts Ave., Cambridge, MA Value-based health care is one of the most pressing topics in health care finance and policy today. Value-based payment structures are widely touted as critical to…

  • Read more: How to “Lower Drug Prices” Without Lowering Drug Prices

    How to “Lower Drug Prices” Without Lowering Drug Prices

    By Rachel Sachs Yesterday, Alex Azar was sworn in as the Secretary for the Department of Health and Human Services. A key question is whether Azar will take action against high drug prices, and if so, what he will do. At his confirmation hearing, Azar stated clearly that “drug prices are too high.” And during…

  • Read more: “Right to Try” Does Not Help Patients

    “Right to Try” Does Not Help Patients

    By Christopher Robertson and Kelly McBride Folkers  In 2014, Arizonans overwhelmingly voted in favor of a ballot referendum that claimed to allow terminally ill patients the “right to try” experimental drugs that have not yet been approved by the Food and Drug Administration (FDA). Despite the policy’s broad support, it has yet to help a…

  • Read more: REGISTER NOW! Will Value-based Care Save the Health Care System?

    REGISTER NOW! Will Value-based Care Save the Health Care System?

    Will Value-based Care Save the Health Care System? March 2, 2018 9:00 AM – 5:00 PM Wasserstein Hall, Milstein East ABC (2036) Harvard Law School, 1585 Massachusetts Ave., Cambridge, MA Value-based health care is one of the most pressing topics in health care finance and policy today. Value-based payment structures are widely touted as critical to…

  • Read more: Will the Sun Shine All Over Canada? Making Transparent the Financial Relationships of the Medical Industry (Part 2: Towards Effective Transparency)

    Will the Sun Shine All Over Canada? Making Transparent the Financial Relationships of the Medical Industry (Part 2: Towards Effective Transparency)

    By Jean-Christophe Bélisle-Pipon As detailed in Part 1, Ontario government just enacted the Health Sector Payment Transparency Act, a Canadian first in terms of transparency. The act requires that “transfers of value” (or payments), related to medical products (drugs and medical devices), between a payor and a recipient be reported to the Health Ministry. The…

  • Read more: Will the Sun Shine All Over Canada? Making the Financial Relationships of the Medical Industry Transparent (Part 1: Theoretical Transparency)

    Will the Sun Shine All Over Canada? Making the Financial Relationships of the Medical Industry Transparent (Part 1: Theoretical Transparency)

    By Jean-Christophe Bélisle-Pipon While Canada is often viewed positively for its public, comprehensive, universal, and accessible health care system, not all is rosy. Canada often lags behind other countries in terms of pharmaceutical policies. Sometimes, this is advantageous (e.g., delaying the approval of a product to wait for more clinical data or real-world efficiency, so…

  • Read more: Register Now! The Policy, Politics & Law of Cancer Conference, Feb 8-9, 2018 at Yale Law School

    Register Now! The Policy, Politics & Law of Cancer Conference, Feb 8-9, 2018 at Yale Law School

    February 8-9, 2018 at Yale Law School  The Solomon Center for Health Law and Policy at Yale Law School, in collaboration with Smilow Cancer Hospital and Yale Cancer Center, will host a major interdisciplinary conference addressing topics at the cutting edge of cancer policy.  This event will bring together leading figures in the worlds of…